Minoryx and Neuraxpharm complete enrolment in leriglitazone pivotal Phase 3 trial (CALYX) in adult patients with cerebral Adrenoleukodystrophy (cALD)
Top-line results expected in early 2028; trial to support future label expansion in the EU and to enable NDA filing in the US. Mataró, Barcelona, Spain, and Düsseldorf, Germany, 09 September 2026 – Minoryx Therapeutics and Neuraxpharm Group (Neuraxpharm), announce that the last patient has been enrolled in the global Phase 3 clinical trial (CALYX)…
View details